Search Results

designation based upon several criteria: the life threatening and debilitating nature of the condition; the medical Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:

there is currently no approved agent to treat this devastating disease, there is a significant unmet medical Management of symptoms is done through a multidisciplinary approach utilizing medication for motor difficulties (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

About Cardiac Dysfunction Heart disease is the leading cause of death for men, women, and people of most 655,000 Americans die from heart disease each year — that is 1 in every 4 deaths.[2] Heart disease costs the U.S. about $219 billion each year — this includes the cost of health care services, medicines, and lost productivity due to death.[3] Cardiac dysfunctions may be caused by and/or related to many other (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated

"Anavex concluded an exceptional fiscal year 2021 while continuing its momentum, highlighted by the efficient using gene biomarkers of response, applying precision medicine for neurological disorders with unmet medical Planned initiation of a pivotal Phase 2/3 study in Fragile X Syndrome, the most frequent genetic cause Webcast / Conference Call Information: The live webcast of the conference call can be accessed online at https (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated

debilitating disorder with significant co-morbidities and there has not been a mechanistically novel medication It is the second most common neurological disorder and approximately one million people in the United As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become Study participants were allowed to be on stable regimen of anti-Parkinson's disease medications (including MDS-UPDRS = M ovement D isorder S ociety- U nified P arkinson's D isease R ating S cale [2] Source: https

debilitating disorder with significant co-morbidities and there has not been a mechanistically novel medication patients and participating families as well the investigators and clinical site coordinators for their dedication Study participants were allowed to be on stable regimen of anti-Parkinson's disease medications (including projected in any of such statements due to various factors, including the risks set forth in the Company’s most Published 2020 Aug 18. doi:10.1186/s12920-020-00761-6 [3] https://www.anavex.com/post/anavex-life-sciences-announces-presentation-of-phase

Investors can register for free admission by following the instructions on the Rodman & Renshaw web site: http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1

Alzheimer’s disease Alzheimer’s disease is a progressive, irreversible neurological disease and the most According to the World Alzheimer Report 2016, the global cost of dementia was $818 billion in 2015 and (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug About AD/PD 2015 Attracting international medical and scientific professionals from around the world, projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media

factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications About Epilepsy Epilepsy is the most common serious neurological disorder, affecting people of all ages (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media

panel will discuss the latest challenges surrounding the advancement of therapies for the treatment of Post-Traumatic are no more restrictive than the predominant requirements or limitations applied to substantially all medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media

(Anavex) (OTCQX: AVXL), a biopharmaceutical company dedicated to the development of novel drug candidates The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised